Laverock Therapeutics successfully closed an additional seed funding round, raising over £20 million to advance its innovative gene control technologies aimed at improving cancer therapies.

Information on the Target

Laverock Therapeutics is a pioneering gene control company focused on developing disease-responsive advanced therapies. The company has recently closed an additional seed funding round, boosting its total capital raised to over £20 million. This funding round was primarily led by Calculus Capital, with contributions from established investors such as Eli Lilly and Company, Mercia Ventures, EOS, and Maven Capital Partners, alongside a new investor, Norcliffe Capital.

With significant platform development already underway, Laverock has achieved crucial milestones, including the generation of functional data that demonstrates improved tumor control capabilities for its core T-cell and Macrophage programmes. These advancements position the company to transition to lead product selection while showcasing their innovative programmable, tunable, and multiplex gene silencing technologies.

Industry Overview in the Target’s Specific Country

The biotechnology sector in the UK is one of the most vibrant in Europe, characterized by robust investment and a strong pipeline of innovation in advanced therapies. The country's favorable regulatory environment, coupled with its extensive research resources and skill